Quantum Biopharma Ltd. (NASDAQ:QNTM) Short Interest Down 27.1% in April

Quantum Biopharma Ltd. (NASDAQ:QNTM) was the recipient of a significant decline in short interest in April. As of April 15th, there was short interest totaling 180,859 shares, a decline of 27.1% from the March 31st total of 248,253 shares. Currently, 5.2% of the company’s shares are short sold. Based on an average trading volume of 335,381 shares, the short-interest ratio is currently 0.5 days.

Quantum Biopharma Price Performance

NASDAQ QNTM traded down $0.18 during trading on Friday, reaching $5.55. 359,231 shares of the company’s stock were exchanged, compared to its average volume of 323,215. The stock has a market capitalization of $21.18 million, a P/E ratio of -0.64 and a beta of 0.13. Quantum Biopharma has a fifty-two week low of $2.07 and a fifty-two week high of $38.25. The business has a 50 day moving average price of $3.58 and a 200-day moving average price of $6.67.

Quantum Biopharma (NASDAQ:QNTM) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.49).

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Platform Technology Partners acquired a new position in shares of Quantum Biopharma in the first quarter valued at about $199,000. Virtu Financial LLC bought a new position in shares of Quantum Biopharma during the fourth quarter worth approximately $76,000. Finally, Jane Street Group LLC acquired a new stake in shares of Quantum Biopharma in the fourth quarter valued at approximately $80,000. Institutional investors own 1.24% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on QNTM. Weiss Ratings reissued a “sell (e+)” rating on shares of Quantum Biopharma in a research report on Friday, March 27th. Wall Street Zen upgraded shares of Quantum Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.